55 results about "Artery diseases" patented technology

This application is directed to systems, methods, and devices for image based analysis of plaque. In some embodiments, the approaches herein can be used for developing treatment plans, which can include local treatment, systemic treatment, or both. In some embodiments, the approaches herein can be used for stent selection. In some embodiments, the approaches herein can be used for surgical planning, which can include robotic surgical planning. In some embodiments, the approaches herein can be used for image normalization. In some embodiments, the approaches herein can be used for identifying plaque calcification thresholds. In some embodiments, the approaches herein can be used for identifying thin cap fibroatheroma. In some embodiments, the approaches herein can be used for coronary artery tree reconstruction. Some embodiments are directed to coronary artery disease risk stratification.

This application is directed to systems, methods, and devices for image based analysis of plaque. In some embodiments, the approaches herein can be used for developing treatment plans, which can include local treatment, systemic treatment, or both. In some embodiments, the approaches herein can be used for stent selection. In some embodiments, the approaches herein can be used for surgical planning, which can include robotic surgical planning. In some embodiments, the approaches herein can be used for image normalization. In some embodiments, the approaches herein can be used for identifying plaque calcification thresholds. In some embodiments, the approaches herein can be used for identifying thin cap fibroatheroma. In some embodiments, the approaches herein can be used for coronary artery tree reconstruction. Some embodiments are directed to coronary artery disease risk stratification.

To provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue.SOLUTION: In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and / or energy are effective in injuring or damaging tissue, nerves and nerve endings in order to relieve disease symptoms.SELECTED DRAWING: Figure 3B

A polygenic risk score (PRS) for coronary artery disease, a construction method therefor, and an application thereof in combination with clinical risk assessment. The present invention first provides an application of a reagent for detecting individual information in preparation of a detection device for assessing the onset risk of the coronary artery disease, wherein the individual information comprises 311 CAD-related single nucleotide polymorphic sites, and the individual information preferably also comprises one or more of BP, BMI, DM, TC and Stroke-related single nucleotide polymorphic sites. The present invention further provides a method for constructing a comprehensive metaPRS for the coronary artery disease. In the present invention, the PRS and the conventional clinical risk factor score are further integrated, such that re-layering of the onset risk of the coronary artery disease can be realized. The present invention is of great significance to primary prevention of the coronary artery disease.

The invention discloses a coronary artery thrombectomy device and a use method thereof. The invention relates to an embolectomy device comprising an embolectomy head which is particularly designed to be deployable in a complex coronary artery system in order to optimally treat coronary artery diseases. The thrombector head may include a deployable framework having a plurality of branches that are in a closed state in a first position and an expanded state in a second position from which the framework expands radially away from the longitudinal axis, thereby enabling mechanical opening of an intravascular embolism pathway, and the operation can be repeated for multiple times in the folded state and the expanded state. The framework may include a capture protection net surrounding a distal end of the framework for capturing thrombus and fragments thereof. The thrombectomy device can be used for working in a straight and bent vascular system. In the thrombus removal process, the head of the thrombus extraction device can be inserted into the thrombus by using a proper guide wire; and then framework expansion is carried out to take out thrombus.

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis, and chronic obstructive pulmonary disorder (COPD).

The invention provides an application of a super enhancer inhibitor JQ-1 in preparation of peripheral artery disease related drugs, relates to the technical field of biomedicine, and discloses a core effect of the super enhancer inhibitor JQ-1 in peripheral artery disease ischemia repair. The traditional Chinese medicine composition can significantly accelerate blood flow recovery of ischemic limbs, up-regulate mRNA and protein expression of a vascular marker CD31 in gastrocnemius muscle tissues, effectively increase vascular density and promote angiogenesis. Aiming at the defects of the existing treatment means in the aspect of ischemic tissue angiogenesis, the application provides a brand new molecular targeted treatment scheme for high-risk groups such as patients with diabetes-related peripheral artery diseases, and can significantly reduce the risk of lower limb amputation and the incidence rate of related cardiovascular adverse events such as coronary heart disease and stroke; the technical blank of specific targeted therapy of peripheral artery diseases is filled, a solid scientific basis and a key direction are provided for research and development of novel drugs, and the specific targeted therapy method has extremely high clinical application value and wide research and development prospects.

The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; R2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R3, R4, R5, R6, R7 and R8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R2, R3, R4 is H; X1, X2, X3, X4, X5 and X6 are independently N or C; with the proviso that in each ring maximal one X is N.

Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

This invention relates to methods of lowering plasma levels of endothelial lipase (EL) in patients in need thereof comprising administering MEDI5884 to subjects at a dose of from about 50 mg to about 600 mg per month.

The present disclosure relates to pharmaceutical formulations of angiotensin converting enzyme inhibitor and / or diuretic, particularly stable oral pharmaceutical formulations comprising angiotensin converting enzyme inhibitor and / or diuretic with one or more pharmaceutically acceptable excipients for the treatment of hypertension, coronary artery disease, heart failure, acute myocardial infarction and other related cardiovascular diseases.

The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: Pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack, angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis, atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

A siRNA for inhibiting LPA gene expression, and a modifier and the use thereof, belonging to the field of biomedicine. Provided are a double-stranded RNA molecule targeting an LPA gene, and a modifier thereof. Both in vivo and in vitro experiments show that the provided double-stranded RNA molecule can effectively inhibit LPA gene expression, and can be used for preventing and / or treating Lp(a)-related diseases, such as thrombosis, atherosclerotic thrombosis, coronary artery disease, ischemic strokes, aortic valve stenosis, heart failure, atrial fibrillation, and peripheral artery disease.

A nanostructural sensing substrate includes indium tin oxide (ITO) film coated upstanding silicon nanowires (ITO / USNWs). The ITO / USNWs are fabricated by coating an ITO film on USNWs, the density of which has been reduced using a facile Ag-assisted chemical etching method. Furthermore, the bioreceptor modified ITO / USNWs are developed to serve as the sensing substrate of the EGFETs device for label-free diagnosis of biomarker related diseases, such as Alzheimer's disease (AD), acute myocardial infarction, coronary artery disease (CAD), hepatic encephalopathy, lung fibrosis, Cushing's syndrome and cancers. The ITO-coated-USNWs are also used in nano-featured cell based biosensors (CBB) for electrically quantitative evaluation of drug release.

The invention discloses a coronary artery disease early risk prediction and typing method based on deep learning, and belongs to the technical field of medical image processing. According to the method, cardiac angiography CTA image pixel-level segmentation is completed by using an image segmentation model, loss is optimized by using a medical image text feature fusion module and multi-modal feature alignment, and early risk prediction and typing of coronary artery diseases are completed. By introducing the multi-scale state space feature encoder, the hierarchical feature reconstruction module and the multi-modal feature alignment optimization loss module, efficient and accurate segmentation and risk assessment of the coronary artery CTA image are realized, a new technical means is provided for segmentation and risk assessment of the coronary artery CTA image, and the segmentation and risk assessment efficiency of the coronary artery CTA image is improved. The development of a multi-modal fusion technology in the field of medical image processing is promoted, powerful support is provided for early diagnosis, risk stratification and personalized treatment of coronary artery diseases, and the method has wide application prospects and important practical value.

Various embodiments described herein relate to systems, devices, and methods for non-invasive image-based plaque analysis and risk determination. In particular, in some embodiments, the systems, devices, and methods described herein are related to analysis of one or more regions of plaque, such as for example coronary plaque, using non-invasively obtained images that can be analyzed using computer vision or machine learning to identify, diagnose, characterize, treat and / or track coronary artery disease.

Methods of treating diseases and conditions in human subjects in need thereof using pharmaceutical compositions comprising an ANGPTL3 RNAi agent are described, the treatment being partially mediated by reducing expression of the ANGPTL3 gene. When administered to a human subject in need thereof according to the methods disclosed herein, the disclosed pharmaceutical compositions comprising an ANGPTL3RNAi agent treat diseases and conditions associated with elevated triglyceride (TG) levels and / or elevated low density lipoprotein cholesterol (LDL-C), such as hypertriglyceridemia (including severe hypertriglyceridemia (SHTG)), homozygous familial hypercholesterolemia (HoFH), hypertriglyceridemia-induced pancreatitis, metabolic syndrome, obesity, hyperlipidemia, mixed dyslipidemia, abnormal lipid and / or cholesterol metabolism, atherosclerosis, cardiovascular disease, type II diabetes, coronary artery disease, and the like. The present invention relates to compounds of formula (I), in particular to compounds of formula (I), such as non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, heterozygous familial hypercholesterolemia (HeFH), statin-resistant hypercholesterolemia, other dyslipidemia, and other metabolism-related conditions and diseases.

To provide an inhibitor of aldose reductase.SOLUTION: There are a new compound and its pharmaceutical composition, and various treatments of other disorders such as a method for promoting health aging of skin, treatment of dermopathy, treatment of cardiovascular disorder, treatment of nephropathy, treatment of angiogenic disorder such as cancer, treatment of tissue damage such as non-heat tissue damage, treatment of progressive myocardial infarction, treatment of ischemia damage, and treatment of complications caused by diabetes, which use the compound and the composition. The other damages are not limited to above, and can include atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, skin infectious disease, peripheral vascular disease, cerebral stroke, galactose blood disease, asthma, and PMM2-CDG.SELECTED DRAWING: None

The present invention discloses a compound represented by formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention also provides the use of the compound, its stereoisomer or pharmaceutically acceptable salt in the preparation of a drug for treating and / or preventing diseases associated with FXIa receptors, especially in the preparation of a drug for treating and / or preventing cerebrovascular arterial disease and / or peripheral arterial disease.

Providing quinazolindione compounds and their uses. [Solution] Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.

Disclosed are compounds of Formula I, or a salt thereof:where A, B, D, X, R1, R2 and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

A computer-implemented method is proposed that utilizes medical imaging (i.e., invasive coronary angiography, invasive optical coherence tomography, or other catheter-based imaging and / or non-invasive computed tomography) to generate a 3D computer model of the arteries / vasculature to provide a risk score that predicts future changes in coronary artery disease based on artificial intelligence and biomechanical simulation. The computer-implemented method preferably analyzes images from one or more imaging systems to extract data regarding arterial structure and function, including augmenting or simulating missing information, and generates the 3D geometry and predicted outcomes of the artery or arterial system.

Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

The invention relates to the technical field of intelligent medical treatment, in particular to a method and device for predicting coronary artery diseases based on porphyromonas gingivalis concentration, and the method comprises the following steps: obtaining a sample data set; preprocessing the sample; selecting a plurality of machine models based on machine learning; screening of feature variables: inputting the sample data set into a plurality of machine models for training, and screening the feature variables in the first feature variable set in combination with a corresponding algorithm to obtain a maximum contribution degree feature variable set; each machine model is correspondingly screened to obtain a maximum contribution degree feature variable set; retraining the corresponding machine model based on the maximum contribution degree characteristic variable set, and evaluating performance indexes through a Bootstrap resampling method to obtain an optimal machine model; and based on the optimal machine model and the maximum contribution degree characteristic variable set, constructing a coronary artery disease prediction model and performing prediction.

The present disclosure relates to pharmaceutical formulations of angiotensin converting enzyme inhibitor and / or diuretic, particularly stable oral pharmaceutical formulations comprising angiotensin converting enzyme inhibitor and / or diuretic with one or more pharmaceutically acceptable excipients for the treatment of hypertension, coronary artery disease, heart failure, acute myocardial infarction and other related cardiovascular diseases.

Belongs to the technical field of medicine and health, and provides application of a novel compound containing a diaza subunit sulfonyl structure as a PKM2 agonist. The compound can be used for treating diseases related to PKM2 mediated regulation, including but not limited to tumors, immune diseases, hair loss, metabolic diseases, proliferation-dependent diseases, coronary artery diseases, Bloom syndromes, pulmonary arterial hypertension and the like. The specific diseases also relate to liver cancer, lung cancer, colorectal cancer, glioblastoma, breast cancer, kidney cancer, inflammatory bowel disease, ulcerative colitis, alopecia, lusterless disease, less hair and the like.

Early diagnosis of cardiovascular diseases can potentially cure subjects and save innumerable lives. Diagnosis and treatment of subjects at early stages by cardiologists remain a challenge. Here, the inventors have measured baseline sTREM-1 (triggering receptor expressed on myeloid cells-1) in 10,000 initially healthy participants without prevalent cardiovascular disease (CVD) from the Paris Prospective Study 3 (PPS3). They have quantified the association and predictive value of baseline sTREM-1 for incident CVD events over 10 years of follow-up. The analysis reveals strong, significant and independent association with incident CVD events combined and its subtypes (coronary heart disease, stroke, peripheral artery diseases, and heart failure). Furthermore, adding sTREM-1 to existing risk prediction algorithms such as SCORE2 or the US pooled risk equation improved the discrimination capacity of these models in a significant and more importantly in a clinically meaningful manner, including among those at moderate CVD risk. Furthermore, the inventors have examined CVD events such as aneurysm, arrythmias and thromboembolic events. Given the ongoing development of pharmacological molecules blocking blood sTREM-1, the inventors believe these findings support future intervention trials testing to which extent sTREM-1 could be a relevant target for the primary prevention of CVD in the general population.

The present disclosure pertains to compositions and methods for the treatment and / or prevention of one or more of obesity, diabetes, metabolic syndrome, Alzheimer's disease, Chronic Fatigue Syndrome (CFS), aging, fibromyalgia, dyslipidemia, hypercholesterolemia, dyslipidemia, Parkinson's disease, migraines, Traumatic Brain Injury (TBI), Attention Deficit Disorder (ADD) / Attention Deficit Hyperactivity Disorder (ADHD), Cancer, Cardiovascular Disease (CVD) / Coronary Artery Disease (CAD), Chronic Pain, neuralgia, depression, amyotrophic lateral sclerosis (ALS), and epilepsy, Insufficient Cellular Energy (ICE) and mitochondrial dysfunction. The present disclosure also pertains to methods for increasing mental and / or physical performance levels and / or decreasing exertion during exercise in a subject by the administration of C5 ketones.